An assortment of research across clinical and basic science fields was on full display at this year’s UB Resident and Fellow Research Day, which took place May 30 in the Jacobs School of Medicine and ...

Abstract: This paper presents a new approach to indexing videos of presentations which use electronic slides. By determining the images of slides in the video frames, and then matching the video ...

Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis ...

Objectives We performed a systematic review and network meta-analysis (NMA ... each eligible article and inserted in tables in Microsoft Word to facilitate analysis and presentation. For the ...

We, therefore, assessed, using a cumulative meta‐analysis, whether at any time point since 1999 had soy foods failed to lower serum cholesterol and found that LDL cholesterol reductions for soy ...

However, their effect on hyperkalemia has not been systematically evaluated. In this meta-analysis of nearly 50 000 participants from clinical outcome trials of sodium glucose cotransporter 2 ...

"We are honored that our Trial in Progress poster has been accepted for presentation at ASCO 2025," said Anastasios Maniakas, MD, PhD, Assistant Professor in the Department of Head and Neck ...

Presenter: Eunice S. Wang, M.D. A post-hoc analysis of the pivotal cohort from the Phase 1/2 study evaluated outcomes in patients with R/R mIDH1 AML who received olutasidenib after either 1-2 or ...

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...

With two abstracts selected for rapid oral presentation, these data reflect the Company’s vision to address cancer across multiple fronts and provide innovative medicines to as many patients as ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ®) technology, today ...